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Abstract
Aims Dilated cardiomyopathy (DCM) is a complex disease where genetics interplay with extrinsic factors. This study aims to
compare the phenotype, management, and outcome of familial DCM (FDCM) and non‐familial (sporadic) DCM (SDCM) across
Europe.
Methods and results Patients with DCM that were enrolled in the prospective ESC EORP Cardiomyopathy & Myocarditis
Registry were included. Baseline characteristics, genetic testing, genetic yield, and outcome were analysed comparing FDCM
and SDCM; 1260 adult patients were studied (238 FDCM, 707 SDCM, and 315 not disclosed). Patients with FDCM were
younger (P < 0.01), had less severe disease phenotype at presentation (P < 0.02), more favourable baseline cardiovascular
risk profiles (P ≤ 0.007), and less medication use (P ≤ 0.042). Outcome at 1 year was similar and predicted by NYHA class
(HR 0.45; 95% CI [0.25–0.81]) and LVEF per % decrease (HR 1.05; 95% CI [1.02–1.08]. Throughout Europe, patients with FDCM
received more genetic testing (47% vs. 8%, P < 0.01) and had higher genetic yield (55% vs. 22%, P < 0.01).
Conclusions We observed that FDCM and SDCM have significant differences at baseline but similar short‐term prognosis.
Whether modification of associated cardiovascular risk factors provide opportunities for treatment remains to be investigated.
Our results also show a prevalent role of genetics in FDCM and a non‐marginal yield in SDCM although genetic testing is largely
neglected in SDCM. Limited genetic testing and heterogeneity in panels provides a scaffold for improvement of guideline
adherence.
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Introduction
Dilated cardiomyopathy (DCM), defined as left ventricular
dilation and systolic left ventricular (LV) impairment unex-
plained by coronary artery disease or abnormal loading
conditions, is a leading cause of heart failure and heart trans-
plantation with an estimated prevalence of ~36 cases per
100 000 in Europe.1
Prior studies on clinical characteristics of patients with
non‐familial (sporadic) forms of DCM (SDCM) and familial
DCM (FDCM) have reported that FDCM presents at earlier
age but presented conflicting evidence regarding phenotype
severity. Some studies found more favourable clinical profiles
in FDCM compared with SDCM, whereas others report similar
baseline phenotypes without any distinctive features.2–5 Due
to genotype–phenotype associations, such as frequent
ventricular arrhythmias in LMNA and PLN mutation carriers,
heterogeneity in prognosis however may be expected
between FDCM and SDCM.6 Others postulated that FDCM
presents as SDCM and that proper active family screening is
needed to distinguish true SDCM from undetected FDCM.
This screening has been shown to effectively identify DCM
and improve prognosis.3
Many studies have shown that DCM can be inherited as a
genetic trait1,7–11 and that structural or functional LV abnor-
malities are present in 20% of asymptomatic relatives of pa-
tients with DCM.12,13 Genetic mutations are reported in
more than a third of index patients with FDCM and in
8–25% of SDCM.8,14 The most common disease causing vari-
ants are found in genes coding for sarcomere proteins such
as TTN, MYH7, and FLNC, and the nuclear envelope gene
LMNA.15–17 Evidence also suggests that genetic predisposi-
tion in DCM may interact with extrinsic disease triggers such
as toxin exposure (ethanol, chemotherapy, and cocaine), viral
infection, and pregnancy.1,18,19 Nonetheless, toxin exposure
may also be the sole putative trigger of DCM, for instance
in alcoholic cardiomyopathy.18
The ESC EORP Cardiomyopathy & Myocarditis Registry is a
prospective observational multinational survey of consecu-
tive patients with cardiomyopathies.20 To investigate the
complexity in clinical characteristics and genetic yield, the
current analysis of this registry aims to (i) study clinical
cardiovascular differences in adult FDCM and SDCM, (ii)
report the frequency of genetic testing across Europe, and
(iii) report differences in genetic yield between familial and
sporadic DCM.
Methods
The general policy as well as baseline results of the new
EURObservational Research Programme (EORP) cardiomyop-
athy registry of the ESC have been previously published. In
short, the EORP cardiomyopathy registry is a multicentre reg-
istry where participating centres were asked to enter base-
line, follow‐up, and genetic data of about 40 consecutive
patients with cardiomyopathy per centre.20 Patients were
included from 1 December 2012 until 30 December 2016.
Inclusion/exclusion criteria
Adult patients with DCM defined by ESC consensus criteria
were studied. Specifically, (i) left ventricular ejection fraction
<45% (>2 SD) and/or fractional shortening <25% (>2 SD),
as ascertained by echocardiography, radionuclide scanning,
or cardiac magnetic resonance imaging; and (ii) left ventricu-
lar end‐diastolic diameter >117% of the predicted value
corrected for age and body surface area (Henry’s formula),
which corresponds to 2 SD of the predicted normal limit +5%.
Patients with heart failure attributable to coronary artery dis-
ease and clinically suspected or biopsy‐proven myocarditis
were excluded.20,21
Definitions
Familial dilated cardiomyopathy (FDCM) was defined by the
presence of two or more affected individuals in a single family
or the presence of an index patient with DCM and a first de-
gree relative with documented unexplained sudden cardiac
death at <35 years of age. Patients that did not meet these
criteria were deemed sporadic DCM (SDCM). Patients with
missing data concerning familial status (n = 315) were com-
pared with both FDCM and SDCM for clinical differences to
account for bias. Primary outcome was defined as a compos-
ite of cardiovascular death, implantation of a ventricular
assist device, or heart transplantation. Secondary endpoint
was hospitalization for urgent cardiac reason. Genetic testing
and variant classification were planned and performed
according to clinician’s judgement. Genetic variants and their
classifications were reported by individual researchers
representing their centres. Because lab techniques and
genetic coordinates were not recorded, centralized variant
classification was not possible. The definitions of included
variables have been listed in prior EORP publications and
are included in the Supporting Information, Data S1.20,22
Statistical analysis
Univariable analysis was applied to both continuous and
categorical variables. Continuous variables were reported
as mean ± standard deviation and/or as median and
interquartile range (IQR) when appropriate. Among‐group
comparisons were made using a non‐parametric test
(Kruskal–Wallis). Categorical variables were reported as
counts and percentages. Among‐group comparisons were
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made using a χ2 test or a Fisher’s exact test if any expected
cell count was less than 5. Plots of Kaplan–Meier curves for
primary outcome were performed. Cox proportional hazards
model was used for survival estimates reporting hazard ratios
(HRs) and 95% confidence intervals (95% CIs) in univariable
and multivariable analysis. As the goal was to report covari-
ates and their association to outcome rather than a clinical
risk calculator, both multivariable results and variable selec-
tion (P < 0.05) were reported. To compare with external
datasets, comparison of proportions was calculated using
the “N‐1” χ2 test. A two‐sided P‐value of <0.05 was consid-
ered as statistically significant. For sensitivity analyses, pro-
bands of FDCM were compared with SDCM. Analyses were
performed using SAS statistical software version 9.4 (SAS
Institute, Inc., Cary, NC, USA).
Results
The cohort comprised 1260 patients, of whom 238 had
FDCM, 707 SDCM, and 315 were unclassified (unknown).
Patients with unknown status were compared with FDCM
and SDCM. The analysis revealed the ‘unknown’ group to
be similar to SDCM. These results and head to head group
comparisons are available in the Supporting Information,
Data S2.
The characteristics and treatment of patients with FDCM
and SDCM are reported in Table 1. Compared with SDCM, pa-
tients with FDCM were younger (44 years [IQR 31–52]) vs.
51 years [IQR 41–58], P < 0.001), had lower NYHA class
(P < 0.001) and BNP and NT‐proBNP levels (P < 0.028), less
frequent left bundle branch block (9% vs. 22%, P < 0.001),
smaller left ventricular end diastolic diameter (P < 0.001),
and higher left ventricular ejection fraction (LVEF) (37% vs.
31%, P < 0.001). Sixty per cent of FDCM patients were index
cases compared with 99% of SDCM patients (P < 0.001).
Patients with SDCM had a higher burden of cardiovascular
risk factors (hypertension, dyslipidaemia, diabetes, smoking,
alcohol intake, and high BMI than FDCM (all P ≤ 0.007). A
larger proportion of patients with SDCM received beta‐
blockers, diuretics, mineralocorticoid receptor antagonists,
and other anti‐arrhythmic agents (P ≤ 0.042) compared with
FDCM. A sensitivity analysis comparing solely FDCM index
patients with SDCM showed that all characteristics except
BMI remained significantly different between the groups
(Supporting Information, Data S2, Table 1.1.A).
Follow‐up data were available in 1105 (88%) cases (median
follow‐up duration: 372 days; interquartile range [IQR]
363–428). There were no differences observed in primary
and secondary outcomes or all‐cause mortality when compar-
ing FDCM (n = 209) to SDCM (n = 611) (Supporting Informa-
tion, Data S2, Table 3B). Age at first primary event was also
similar for FDCM and SDCM (Figure 1).
In multivariable analysis, BMI per unit decrease (HR 1.11;
95% CI [1.02–1.22]) and LVEF per % decrease (HR 1.08; 95%
CI [1.03–1.11]) were associated with primary and secondary
outcomes. After stepwise selection, NYHA class I/II versus
III/IV (HR 0.45; 95% CI [0.25–0.81]) and LVEF per % decrease
(HR 1.05; 95% CI [1.02–1.08] were predictive (Table 2). There
were no significant associations for all‐cause mortality.
Results of all analyses are available in the Supporting Informa-
tion, Data S2, Table 10.
Genetic testing
In total, 214 out of the 1260 (17%) cases were genetically
tested (58 out of 707 [8%] SDCM and 114 out of 238 [48%]
of FDCM). In 110 cases, the information on genetic testing
was missing. Genetic testing was less frequently performed
in Eastern Europe and North Africa (respectively 4% and
0%), whereas North, South, and West Europe performed
genetic testing in 21–27% of their population (Table 3).
In 63 out of the 114 (55%) tested cases of FDCM, at least
one disease causing variant was reported compared with 13
out of 58 (22%) in SDCM. These variants were most prevalent
in sarcomere (n = 42) and nuclear genes (n = 27), with most
variants being discovered in LMNA (16% yield in FDCM and
3% yield in SDCM) and MYH7 (14% yield in FDCM and 0% in
SDCM) (Supporting Information, Data S2, Table 7).
Discussion
The three main findings of this study are (i) patients with
FDCM present at younger age with a less severe phenotype
and lower burden of cardiovascular risk factors but similar
short‐term prognosis to SDCM; (ii) patients with FDCM are
genetically tested more frequently and with higher diagnostic
yield than SDCM and; (iii) there are important differences in
the use of genetic testing across European centres enrolled
in the ESC cardiomyopathy registry. For a central illustration,
these findings are summarized in Figure 2.
Disease burden
Overall, DCM patients included in this cohort had similar
demographic and clinical characteristics compared with
DCM populations described in the literature.2,4,5,12,23
However, in contrast to some studies, we found that pa-
tients with FDCM were diagnosed at a younger age and
have a less severe phenotype than patients with SDCM
but have similar cardiovascular prognosis.2,5 This was also
seen in the prescribed medication, where we observed that
patients with FDCM received less beta‐blockers, diuretics
and mineralocorticoid receptor antagonists. These findings
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may reflect of cascade family screening in patients with
suspected FDCM. However, when comparing FDCM index
patients with SDCM patients, the clinical differences
remained significant. Because family screening has shown
to effectively identify DCM patients at earlier stages of
disease, potentially benefiting prognosis, genetic counselling
remains an important pillar of care in patients with DCM
and their relatives.3 Prognosis of DCM has been improving
for the endpoint of cardiovascular death of heart transplan-
tation/assist device implantation, arguably because of bet-
ter cardiovascular care and the early identification and
classification of disease.24 Our observations however are
more in line with earlier reports and less favourable
outcome, which may be caused because of a selection bias
towards more expert/tertiary centres.23
A relevant finding of this study was that patients with
SDCM had a higher burden of cardiovascular risk factors, such
as hypertension, hypercholesterolaemia, and smoking.
Because it is well known that these risk factors are more
prevalent with increasing age, and our patients with SDCM
were significantly older than FDCM, this result might be
expected.25 However, the age difference between SDCM
and FDCM does not fully account for the observed increase
in risk factors. When comparing our patients with SDCM with
external cohorts from the same age group, we still observe a
significantly increased burden of cardiovascular factors
Table 1 Baseline table of patient characteristics, pharmacotherapy and outcome
All (N = 1260) FDCM (n = 238) SDCM (n = 707) P‐valuea
Age at diagnosis (years), median (IQR) 49 (40–58) 44 (31–52) 51 (41–58) <0.01
Male <0.05
NYHA class <0.01
I 935 (74%) 165 (69%) 536 (76%)
II 198 (19%) 65 (35%) 84 (14%)
III 448 (43%) 79 (42%) 261 (44%)
IV 316 (30%) 37 (20%) 187 (31%)
Family history of SCD 87 (8%) 6 (3%) 65 (11%) <0.01
Hypertension 479 (38%) 54 (23%) 288 (41%) <0.01
Dyslipidaemia 472 (38%) 62 (26%) 274 (39%) <0.01
Diabetes Mellitus 211 (17%) 25 (11%) 127 (18%) <0.01
Alcohol use ≥ 1 units/day 174 (16%) 20 (10%) 124 (20%) <0.01
Smoking (current and former) 507 (42%) 71 (31%) 323 (47%) <0.01
Renal impairment 172 (14%) 24 (10%) 94 (13%) 0.20
History of Atrial Fibrillation 356 (28%) 63 (27%) 202 (29%) 0.53
History of Stroke 87 (7%) 12 (5%) 47 (7%) 0.38
History of resuscitation 61 (5%) 15 (6%) 32 (5%) 0.28
Atrioventricular block 0.02
1st 108 (9%) 20 (9%) 57 (8%)
2nd 6 (1%) 3 (1%) 2 (0%)
3rd 14 (1%) 6 (3%) 4 (1%)
QRS Duration (ms), median, IQR 105 (92–130) 100 (90–112) 104 (90–130) 0.02
LBBB 219 (21%) 18 (9%) 133 (22%) <0.01
RBBB 41 (4%) 6 (3%) 24 (4%) 0.53
LVEF (%), median (IQR) 31 (25–40) 37 (29–45) 31 (24–40) <0.01
LVEDD (mm), median (IQR) 64 (58–70) 60 (54–67) 64 (59–70) <0.01
Diastolic dysfunction (grades) <0.01
Normal 63 (38%) 97 (20%)
I (impaired relaxation) 57 (35%) 169 (35%)
II (pseudonormal) 28 (17%) 108 (22%)
III/IV (restrictive) 16 (9%) 109 (22%)
Haemoglobin (g/dL), median (IQR) 14 (13–15) 14 (13–15) 14 (13–15) 0.23
BNP (pg/mL), median (IQR) 297 (72–717) 108 (36–555) 404 (106–718) 0.03
NT‐proBNP (pg/mL), median (IQR) 1102 (312–3341) 589 (156–1663) 1276 (452–3527) <0.01
Performed 259 (21%) 66 (28%) 148 (21%) 0.04
Abnormal 237 (19%) 57 (24%) 136 (19%) 0.04
Late gadolinium enhancement 153 (64%) 41 (65%) 92 (67%) 0.83
β ‐blockers 1130 (90%) 203 (85%) 644 (91%) 0.01
Diuretics 895 (72%) 123 (54%) 540 (77%) <0.01
ACE‐inhibitors or ATII‐receptor blockers 1121 (89%) 208 (88%) 634 (89%) 0.329
Mineralocorticoid receptor antagonists 795 (63%) 119 (50%) 470 (67%) <0.01
Other antiarrhythmics 361 (29%) 56 (24%) 215 (30%) 0.04
BMI, body mass index; LBBB, left bundle branch block; LVEDD, left ventricular end diastolic diameter; LVEF, left ventricular ejection frac-
tion; NYHA, New York Heart Association; RBBB, right bundle branch block; SCD, sudden cardiac death.
Data are presented as number and percentages of valid. Patients with missing family status were not included in the subgroup SDCM in
this table because their status was unknown. They have been included in the Supporting Information, Data S2, Table 1 both a separate
group and combined with SDCM. Continuous data are presented as medians. Median presented with first and third interquartiles
(IQR). Mean presented with ±standard deviation (SD).
aFDCM versus SDCM.
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(P < 0.01) in our patients with SDCM.25,26 In addition, the
presence of common cardiovascular risk factors is also associ-
ated with worse outcome in SDCM. Smoking, for instance,
independently increased sudden cardiac death in SDCM27
and diabetes confers a two‐fold to five‐fold added risk for
heart failure development, even after adjustment for other
traditional risk factors such as coronary heart disease.22
Alcohol is also known to be the both sole cause of cardiomy-
opathy and may negatively affect cardiac function in
mutation carriers. In a recent report including 716 DCM
cases, excessive alcohol consumption resulted in an absolute
LVEF reduction of ±9% in patients with a truncating TTN
variant.18 These results support the hypothesis that cardio-
vascular risk factors and external toxic substances interplay
with genetic frailty, (auto)immunity, or endocrinological
disorders in the DCM phenotype.1 Whether modification of
cardiovascular risk factors provide opportunities for treat-
ment remains to be investigated.
Differences in prognosis between FDCM and SDCM remain
controversial with most follow‐up studies of DCM not divid-
ing populations in familial and non‐familial categories.3,28,29
Conflicting results of prior studies may be due to the absence
of reliable clinical or morphological parameters to differenti-
ate between FDCM and SDCM.1,3,28,29 Genotype–phenotype
associations affecting prognosis in DCM have been reported:
mutations in LMNA and RBM20 predispose for more/younger
heart transplantations.6 Mutations in FLNC, LMNA, and PLN
have been associated with sustained ventricular arrhythmias
in DCM.30 Nonetheless, our analysis did not yield a significant
difference in outcome between FDCM and SDCM.
Genetic mutations in dilated cardiomyopathy
Mutations in over 40 genes are causally related to DCM and
explain up to 61% of cases in FDCM and up to 25% in
SDCM.1,8,14,16,31 Our data confirm the higher yield in FDCM.8
At present, genetic screening is advised in patients with
family history of DCM or a personal history of atypical
features such as conduction/rhythm‐disturbances,7,8,11,31
and yet less than 50% of all cases in the registry were tested.
Moreover, the fact that heterogeneous screening strategies
were used may have impacted on the yield of testing.20 For
instance, mutations in Titin (TTN) have been implicated in
up to 22% of SDCM, but this gene was only tested in 19%
of our patients with SDCM.32,33 The selective nature of
genetic testing may explain the high prevalence of mutations
in genes coding for sarcomere genes and LMNA.
Genetic testing in Europe
We observed differences in genetic testing between
European centres. Genetic testing was most prevalent in
Northern, Southern, and Western Europe (around 20% of
the cohort) and least common in Eastern Europe and North
Africa. Importantly, Southern Europe included a majority
(54%) of the patients with FDCM in this cohort, which could
have led to sampling bias.34,35 These shortcomings should
be accounted for in terms of external validity of this study.
Furthermore, the regional differences in our study as well
as differences described by prior EORP studies provide oppor-
tunities to improve guideline adherence in Europe.20,35,36
Even though guideline adherence is highest in secondary
and tertiary centres and higher for cardiologists than other
specialities, care may be fragmented in highly complex
diseases such as inherited cardiomyopathies.37 This fragmen-
tation can cause unwanted protocol deviations that may de-
teriorate quality of care. Several strategies have been
suggested to improve guideline adherence. These strategies
include common care pathways, ongoing education, and
focus groups.37 In terms of genetic testing, actively looking
for familial manifestations of disease in patients and relative
and acquiring a detailed family history are quintessential
and may improve genetic yield dramatically.
Study limitations
In contrast to controlled clinical studies, our data are likely to
be heterogeneous given the nature of the study design. As
the structure of the registry requested to introduce patients
Table 2 Multivariable analysis for primary outcome
Variable Pval hazard ratio Hazard ratio (95% CI)
Age at diagnosis per year increase 0.040 (S) 0.973 (0.949; 0.999)
LBBB 0.635 (NS) 0.804 (0.327; 1.977)
NYHA class I or II versus III or IV 0.061 (NS) 0.483 (0.226; 1.035)
Alcohol intake 1 unit per day or more 0.618 (NS) 1.224 (0.553; 2.705)
Body mass index (kg/m2) per unit increase 0.012 (S) 0.896 (0.823; 0.977)
Diabetes mellitus 0.029 (S) 2.815 (1.111; 7.131)
Hypertension 0.859 (NS) 1.070 (0.509; 2.251)
Smoking current of former 0.921 (NS) 0.964 (0.472; 1.970)
LVEF per % decrease <0.001 (S) 1.073 (1.031; 1.117)
LBBB, left bundle branch block; LV, left ventricular ejection fraction; NS, not significant; NYHA, New York Heart Association; S, significant.
Primary endpoint was defined as a composite of cardiovascular death, implantation of a ventricular assist device, or heart transplantation.
Cox proportional hazards model is presented (hazard ratio’s and 95% confidence intervals).
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Figure 1 Survival probability curves for primary outcome plotted over both time and age comparing SDCM to FDCM.
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from expert/tertiary centres, this may have caused a selec-
tion bias. Second limitation is that not all genes were tested
in all patients, and centralized variant classification was not
repeated in this study. Given that genetic testing was
unknown in 110 patients, this might constitute another limi-
tation. Even though myocarditis is formally an exclusion crite-
rion, inflammation‐caused/mediated reasons for DCM are
very difficult to diagnose. Therefore, we cannot exclude with
certainty that a proportion of non‐familial DCM might be
suspected for inflammatory diseases. As the EORP study
was not designed for inter‐regional comparisons, and these
analyses were not planned, such comparisons may be
arbitrary and unrepresentative. Furthermore, sub‐analyses
using ethnicity/race to provide insight into heterogeneity of
Table 3 Regional differences for genetic testing in DCM
All (N = 1260) FDCM (N = 238) SDCM (N = 707) P‐valuea
North Europe (n = 179) 37 (21%) 19 (56%) 11 (16%) <0.001
South Europe (n = 425) 116 (27%) 74 (59%) 23 (14%) <0.001
West Europe (n = 206) 48 (23%) 15 (56%) 24 (16%) <0.001
East Europe (n = 302) 13 (4%) 6 (18%) 0 (0%) <0.001
North Africa (n = 38) 0 (0%) 0 (0%) 0 (0%) NC
Total (1150) 214 (17%) 114 (48%) 58 (8%) <0.001
NC, not calculable.
In 110 cases, genetic testing was unknown.
aFDCM versus SDCM.
Figure 2 Summary of the main findings of this study.
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populations are limited by poor accuracies of ethnicity/race in
electronic health records. Importantly, even though we per-
formed sensitivity analyses with and without patients with
unknown classification, this still might have led to biased re-
sults. Lastly, the fact that no difference in outcome was de-
tected in our DCM populations may be due to sample size
and requires confirmation in larger studies.
Conclusions
Familial DCM and SDCM have significant differences at base-
line. Patients with FDCM appear to present at earlier stage of
disease. Patients with SDCM in this registry have less
favourable clinical profile. Whether modification of associ-
ated cardiovascular risk factors provide opportunities for
treatment remains to be investigated. Genetic testing con-
firms a prevalent role of genetics in FDCM but is largely
neglected in SDCM. Although SDCM may probably be multi-
factorial, genetic influences need further understanding. Lim-
ited genetic testing provides a scaffold for improvement of
guideline adherence.
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